PCR-based assays are increasingly utilized for bioanalysis to support the development of a wide variety of therapeutics. While the largest driver for this growth has been the expanding pipeline of cell, gene, and RNA therapies, PCR-based assays are also seeing increased use in biomarker detection across all therapeutic modalities. These…

Remember that childhood excitement the night before Christmas? Too excited to sleep, knowing something you wished for was finally within reach? That’s exactly the spirit fueling our teams in Lyon as we approach the end of June. We’re eagerly awaiting the arrival of a powerful new platform at our…

Hybrid LC-MS/MS is a technique that combines an affinity capture step with LC-MS/MS detection. It typically requires only one antibody, in contrast to conventional ligand-binding assays (LBAs), which usually need two. This approach leverages the combined selectivity of affinity extraction and the analytical power of tandem mass…

Biomarkers (BMKs) have become fundamental tools in drug development, accelerating and optimizing targeted therapeutic innovation. As a bioanalytical CRO with over 15 years of experience in biomarker analysis, we’ve seen firsthand how the strategic integration of biomarkers can accelerate drug programs, help meet evolving regulatory standards,…

From initial receipt to final disposition, sample integrity, traceability, and compliance are the foundation of our bioanalytical operations. We’re taking you behind the scenes to follow the journey of a sample through our facility.  Here’s a detailed look at each stage in the lifecycle of a study sample at KCAS…